Drug Patents owned by Chiesi

1. List of Bethkis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7939502 CHIESI Optimised formulation of tobramycin for aerosolization
Jun, 2022

(7 months ago)

US6987094 CHIESI Optimized formulation of tobramycin for aerosolization
Sep, 2022

(4 months ago)

US7696178 CHIESI Optimised formulation of tobramycin for aerosolization
Sep, 2022

(4 months ago)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 12 October, 2012

Treatment: Management of cystic fibrosis patients

Dosage: SOLUTION;INHALATION

How can I launch a generic of BETHKIS before it's patent expiration?
More Information on Dosage

2. List of Cardene drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE before it's patent expiration?
More Information on Dosage

3. List of Cleviprex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

Drugs and Companies using CLEVIDIPINE ingredient

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CLEVIPREX before it's patent expiration?
More Information on Dosage

4. List of Ferriprox drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156 CHIESI Liquid formulation for deferiprone with palatable taste
Oct, 2029

(6 years from now)

US10940115 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10780055 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10940116 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11357731 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11458103 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Apr 30, 2024

Drugs and Companies using DEFERIPRONE ingredient

Market Authorisation Date: 09 September, 2015

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL

More Information on Dosage

5. List of Kengreal drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6130208 CHIESI Formulation containing a nucleotide analogue
Jun, 2023

(4 months from now)

US9925265 CHIESI Methods of treating or preventing stent thrombosis
May, 2029

(6 years from now)

US9427448 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Nov, 2030

(7 years from now)

US8680052 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Mar, 2033

(10 years from now)

US9439921 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

US9700575 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

US9295687 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

US10039780 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor; Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion; Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci; Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in